GPX4-IN-3

Cat. No.:	HY-141809		
CAS No.:	2761004-85	-5	
Molecular Formula:	C ₂₉ H ₂₄ ClN ₃ O ₃ S		
Molecular Weight:	530.04		
Target:	Glutathione Peroxidase; Ferroptosis		
Pathway:	Metabolic Enzyme/Protease; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro D	DMSO : 67.5 mg/mL (127.35 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.8867 mL	9.4333 mL	18.8665 mL		
		5 mM	0.3773 mL	1.8867 mL	3.7733 mL		
		10 mM	0.1887 mL	0.9433 mL	1.8867 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 6.75 mg/mL (12.73 mM); Suspended solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6.75 mg/mL (12.73 mM); Clear solution						

BIOLOGICAL ACTIV			
Description	GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM ^[1] .		
In Vitro	 GPX4-IN-3 (26a) exhibits IC₅₀ values of 0.78 μM, 6.9 μM, 0.15 μM and 4.73 μM in 4T1, MCF-7, HT1080 and HT1080 (with Fer-1) cells, respectively^[1]. GPX4-IN-3 (26a) exhibits outstanding GPX4 inhibitory activity with a percent inhibition up to 71.7% at 1.0 μM compared to 45.9% of RSL-3^[1]. GPX4-IN-3 (26a) could significantly induce lipid peroxide (LPO) increase and effectively induce ferroptosis with satisfactory selectivity^[1]. GPX4-IN-3 (26a) is more likely to induce ferroptosis through the accumulation of intracellular peroxides via inhibiting GPX4 		

Product Data Sheet

N=

∬ 0

CI

ö

N H

RedChemExpress

	activity ^[1] . GPX4-IN-3 (26a) significantly increased the level of ROS in 4T1 cells, which could also be reversed by Ferrostatin-1 (fer-1) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	GPX4-IN-3 (26a) exertes antitumor activity and good biological safety in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	15 and 30 mg/kg		
	Administration:	Intravenous injection, every two days for a total of five times.		
	Result:	Significantly suppress tumor growth with a tumor growth inhibition (TGI) value of 33.2 and 55.1% at 15 and 30 mg/kg, respectively.		

CUSTOMER VALIDATION

• J Exp Clin Cancer Res. 2023 Mar 1;42(1):52.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Congjun Xu, et al. Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer. J Med Chem. 2021 Sep 23;64(18):13312-13326.

Caution: Product has not been fully validated for medical applications. For research use only.